A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Clinical trial NCT05993234 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05993234
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-12-05
- Primary completion
- 2026-12-01
- Enrollment
- 257
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.